Open an account

Dyadic International

DYAI · NASDAQ

$0.3851+$0.0042 (+1.10%)TodayMarket closed ·
Prev close $0.3809

About DYAI

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. The company is headquartered in Jupiter, Florida. The company went IPO on 2004-11-05. The firm's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The firm has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Employees
6
Headquarters
Jupiter, Florida
Listed
Nov 5, 2004
Sector
Health Care
Industry
Biotechnology
Website
dyadic.com

DYAI key statistics

Market cap
15.43M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
127.67K
Volume
57.69K
Open price
$0.393
High today
$0.4048
Low today
$0.38
52 Week high
$1.60
52 Week low
$0.3401

Dyadic International (DYAI) at a glance

Dyadic International (DYAI) last traded at $0.3851, with a market cap of 15.43M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.38 and $0.4048. The current price is 1.3% above the day's low and 4.9% below its high.

Volume so far is 57.69K shares, below the average of 127.67K shares a day.

Over the past year Dyadic International has ranged from $0.3401 to $1.60, and now sits 4% of the way up that range.

Dyadic International met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.06 per share against an estimate of -$0.0374.

The average analyst price target is $5.61, 1356.8% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $5.61
Low
$4.04
Now
$0.3851
High
$7.35

DYAI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 44.0% on average.

  1. Q3 FY24: reported -$0.01 per share against an estimate of -$0.0714
  2. Q4 FY24: reported -$0.05 per share against an estimate of -$0.0408
  3. Q1 FY25: reported -$0.07 per share against an estimate of $0.00
  4. Q2 FY25: reported -$0.06 per share against an estimate of -$0.0612
  5. Q3 FY25: reported -$0.06 per share against an estimate of -$0.0442
  6. Q4 FY25: reported -$0.058 per share against an estimate of -$0.0459
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.0408
  8. Q2 FY26: reported -$0.06 per share against an estimate of -$0.0374

DYAI news

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Transcript: Dyadic International Q1 2026 Earnings Conference Call

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Market-Moving News for December 1st

  • A Look at Dyadic International's Upcoming Earnings Report

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseBusiness Wire

    Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

Similar companies

Companies in the same industry as Dyadic International

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.